We therefore applied dSTORM and other techniques to investigate the effect of the HDAC6 inhibitor ricolinostat and the novel HDAC6 inhibitors ACY-241 and WT-161 on CD38 expression levels on myeloma cells and to determine whether upregulation of CD38 is a class effect that works synergistically with daratumumab. This evidence concerns the gene CD38 and plasma cell myeloma.